Anti-Mouse IL-23 p19 Antibody (G23-8)
Based on 1 Customer Validation
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived anti-mouse IL-23 p19 IgG1 monoclonal antibody. Anti-Mouse IL-23 p19 Antibody (G23-8) alleviates inflammation by restoring CLDN8 expression. Anti-Mouse IL-23 p19 Antibody (G23-8) can be used for research on inflammation conditions such as colitis and asthma.
For research use only. We do not sell to patients.
- Purity : 99.14%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
|
IL-23 |
In Vitro
Anti-Mouse IL-23 p19 Antibody (G23-8) (6 μg/mL, 72 h) reverses the significant downregulation of CLDN8 expression by IL23 in NCM460 and Caco-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCM460 and Caco-2 cells
-
Concentration:6 μg/mL
-
Incubation Time:72 h
-
Result:Reversed the significant downregulation of the CLDN8 mRNA level by IL23.
-
Cell Line:NCM460 and Caco-2 cells
-
Concentration:6 μg/mL
-
Incubation Time:72 h
-
Result:Reversed the significant downregulation of the CLDN8 protein level by IL23.
In Vivo
Anti-Mouse IL-23 p19 Antibody (G23-8) (400 μg/mouse, i.p., 1 h before every challenge period, on day 14, 15, 21, and 22) inhibits Th17 activation and neutrophilic inflammation in male C57BL/6 mice induced with Ovalbumin (OVA) or house dust mite (HDM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice (6-8 weeks) induced with Trinitrobenzene sulfonic acid (TNBS)[1]
-
Dosage:0.5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily, for 3 days
-
Result:Significantly alleviated intestinal inflammation.
Restored the expression of CLDN8.
Improved weight and histological score.
Increased intestinal permeability and alleviated myeloperoxidase (MPO) activity.
-
Animal Model:Male C57BL/6 mice induced with OVA or HDM[2]
-
Dosage:400 μg/mouse
-
Administration:Intraperitoneal injection (i.p.), 1 h before every challenge period on day 14, 15, 21, and 22
-
Result:Inhibited Th17 activation and neutrophilic inflammation.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo IL-23p19 neutralization; Western blot
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-23 p19 Antibody (G23-8)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Wang H, et al. Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease. Genome Biol. 2016 Mar 30;17:58. [Content Brief]
[2]. Han S, et al. Distinctive CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis. Nat Commun. 2024 Oct 4;15(1):8628. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)